Publications by authors named "Ruopeng Su"

Claim this Profile
S
Serotonin modulates lineage plasticity in neuroendocrine prostate cancer via epigenetic reprogramming.
Yiyi Ji, Cheng-Wei Ju, Lei Chen, Kai Shen, Ruopeng Su

Cancer Discov· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the CCL5/CCR5 axis in tumor-stromal crosstalk to overcome cisplatin resistance in neuroendocrine prostate cancer.
Bo Liu, Weiwei Zhang, Yiyi Ji, Jiajin Wu, Ruopeng Su

J Exp Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of [F]FDG PET/CT in metastatic hormone-sensitive prostate cancer at initial diagnosis: a retrospective cohort study.
Ang Li, Kai Shen, Yiyi Ji, Weiwei Zhang, Bo Liu, Ruopeng Su

Ann Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study.
Ruopeng Su, Tingxuan Huang, Liangyou Gu, Yige Bao, Zhihong Liu

Cancer Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer.
Yiyi Ji, Weiwei Zhang, Kai Shen, Ruopeng Su, Xinyu Liu

Nat Commun· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway.
Yiyi Ji, Bo Liu, Lei Chen, Ang Li, Kai Shen, Ruopeng Su

Cell Oncol (Dordr)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of salvage partial nephrectomy versus radical nephrectomy after the failure of initial partial nephrectomy.
Jiwei Huang, Ruopeng Su, Cuijian Zhang, Yige Bao, Xiaoyi Hu

Urol Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F-FDG PET/CT imaging in neuroendocrine prostate cancer: Relation to histopathology and prognosis.
Kai Shen, Minghao Yu, Yiyi Ji, Xiang Zhou, Bo Liu, Ruopeng Su

Prostate· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes of immune checkpoint inhibitor plus nab-paclitaxel in metastatic upper tract urothelial carcinoma.
Ruopeng Su, Zeyu Chen, Hailong Hu, Shuai Jiang, Minfeng Chen

Transl Androl Urol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real-world study.
Ruopeng Su, Zeyu Chen, Daoping Hong, Shuai Jiang, Yichu Yuan

Cancer Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-throughput drug screening identifies fluoxetine as a potential therapeutic agent for neuroendocrine prostate cancer.
Lei Chen, Yiyi Ji, Ang Li, Bo Liu, Kai Shen, Ruopeng Su

Front Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy.
Jiwei Huang, Ruopeng Su, Zeyu Chen, Shuai Jiang, Minfeng Chen

Oncoimmunology· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive analysis of androgen receptor status in prostate cancer with neuroendocrine differentiation.
Ruopeng Su, Lei Chen, Zhou Jiang, Minghao Yu, Weiwei Zhang

Front Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Zehua Ma, Weiwei Zhang, Baijun Dong, Zhixiang Xin, Yiyi Ji, Ruopeng Su

Theranostics· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure guided maturation of a novel humanized anti-HBV antibody and its preclinical development.
Bing Zhou, Lin Xia, Tianying Zhang, Min You, Yang Huang, Ruopeng Su

Antiviral Res· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A bispecific broadly neutralizing antibody against enterovirus 71 and coxsackievirus A16 with therapeutic potential.
Bing Zhou, Longfa Xu, Rui Zhu, Jixian Tang, Yangtao Wu, Ruopeng Su

Antiviral Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy.
Lin Xia, Ruopeng Su, Zhiqiang An, Tong-Ming Fu, Wenxin Luo

Hum Vaccin Immunother· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis